SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Natasha B. Leighl,Mary W. Redman,Naiyer A. Rizvi,Fred R. Hirsch,Philip C. Mack,Lawrence H. Schwartz,James L. Wade,William J. Irvin,Sreekanth Reddy,Jeffrey Crawford,Jeffrey D. Bradley,Tom Stinchcombe,Suresh S. Ramalingam,Jieling Miao,Katherine Minichiello,David R. Gandara,Roy S. Herbst,Vassiliki Papadimitrakopoulou,Karen Kelly

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

2020

Natasha B. Leighl
Mary W. Redman
Naiyer A. Rizvi
Fred R. Hirsch
Philip C. Mack
Lawrence H. Schwartz
James L. Wade
William J. Irvin
Sreekanth Reddy
Jeffrey Crawford
Jeffrey D. Bradley
Tom Stinchcombe
Suresh S. Ramalingam
Jieling Miao
Katherine Minichiello
David R. Gandara
Roy S. Herbst
Vassiliki Papadimitrakopoulou
Karen Kelly

9623Background: The Lung Cancer Master Protocol (Lung-MAP) is designed to evaluate novel targeted therapies in patients with advanced squamous lung carcinoma. In the S1400F sub-study (non-match), w...

Keywords:

Oncology
Tremelimumab
acquired resistance
Durvalumab
Squamous cell lung cancer
Internal medicine
previously treated
Phases of clinical research
stage iv
Pathology
Medicine
Lung

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations